Spinal Alignment Solutions, Inc. appears in FDA records as the applicant on two 510(k) clearances for pelvic incidence rod systems, one in 2024 and one in 2026. The company's own website describes a system of six pre-contoured rods matched to patient pelvic incidence categories, with rod shapes reflecting segmental lordosis distributions. Its About page describes SAS as a software planning technology company that uses artificial intelligence and neural network machine learning technologies to plan, predict, and execute surgical care. The supplied filings show a single linked 510(k) record in the current collection, dated September 30, 2026. [1][3][7]

Documented clearances and filing dates

The most recent supplied record is K263172 for the SAS MIS Pelvic Incidence Rods, received September 10, 2026 and decided September 30, 2026 with decision code SESE, meaning substantially equivalent. The FDA letter lists the device under 21 CFR 888.3070, Class II, product code NKB, and identifies the applicant as Spinal Alignment Solutions, Inc. An earlier clearance, K242350, dated October 28, 2024, covers the Spinal Alignment Solutions Pelvic Incidence (PI) Rod System under the same regulation and product code. The company website also lists 510(k) K242350. [1][2][5]

The current collection contains one linked 510(k) record, and its decision count shows one SESE decision; the record sample likewise contains that single entry. These figures describe the supplied filings as of the snapshot date and are not a measure of total company submissions, sales or portfolio breadth. [1]

Product description as published

Company materials describe PI-Rod SEGLIGN as a system of six pre-contoured rods matched to patient pelvic incidence categories, with each rod shape reflecting segmental lordosis distributions derived from successful fusion outcome data. The same materials state that lordotic rod profiles were derived from asymptomatic subjects and successful fusion outcome data, with segmental lordosis targets per level and pelvic incidence. The listed indications cover degenerative disc disease, spondylolisthesis, trauma, spinal stenosis, curvatures, tumor, pseudarthrosis and failed previous fusion, with the Instructions for Use referenced for complete indication, contraindication, warning and precaution information. [3][4]

The 2026 FDA letter describes the subject device as equivalent to the predicate SAS PI-Rods when each is used with the CD Horizon SOLERA Spinal System, and states that the subject device does not introduce a new worst case condition, so no additional mechanical testing was performed. [2]

Company identity and stated focus

The About page states that SAS is a software planning technology company using artificial intelligence and neural network machine learning technologies to plan, predict and execute surgical care. That page lists Leighton LaPierre as Vice President of Marketing, Brandon Arthurs as Vice President of Regulatory, Renaud Lafage as Vice President of Planning Technologies and Miles Wilson as Vice President of Sales, and identifies Bassel Diebo, MD as Chief Medical Officer on a surgeon advisory board. The K263172 record lists Bassel Diebo as contact at a Wilmington, North Carolina address, which is a filing address rather than a verified headquarters. [1][7]

The website footer carries a patent pending notation for US Application No. 19/026,236. No parent company, brand owner or corporate ownership structure is verified in the public documents. [4]

What the record does and does not establish

The public documents document regulatory clearance and product description only. They do not establish clinical outcomes, comparative performance, commercial availability, customers, certifications or firsthand testing, and none should be inferred from the clearances. The 2024 letter concludes substantial equivalence based on test results and comparison to predicate devices, while the 2026 letter relies on previous test results and comparison to the predicate. [2][5]

The Innolitics record for K263172 restates the device name, applicant, product code, decision date and decision, consistent with the FDA entry. Any figure beyond the supplied filings remains unknown. [8]